Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

Switching therapies in MS – what is the evidence?

May 28, 2019

…g for patients with a suboptimal response to a second-line agent. The most commonly-studied scenario is switching from natalizumab to another agent, often due to concerns about the cumulative risk of progressive multifocal leukoencephalopathy (PML). The University of Colorado MS group found that the risk of increased disease activity in the year following a switch from natalizumab to fingolimod depended on the duration of the washout period (Vollm…

AAN 2019 DAILY REPORT

May 9, 2019

…weeks after the last dose of natalizumab. To date, 16 patients were relapse-free at 6 months. However, there were four serious adverse events, including one case each of breast cancer and acute cystitis. Rituximab/ocrelizumab to natalizumab: A small case series reported on three patients who switched from natalizumab to rituximab or ocrelizumab, then switched back to natalizumab (Vollmer et al. AAN 2019; abstract P3.2.103). Patients restarted nata…

AAN Poster Picks – Tuesday, May 7, 2019

May 7, 2019

…038, P3.2-043, P3.2-063), ibudilast (P3.2-049) Neurofilament-light and DMTs: Fingolimod (P3.2-032), alemtuzumab (P3.2-045), ibudilast (P3.2-033), SCT (P3.2-039) Long-term data: DMF (P3.2-084), alemtuzumab (P3.2-037, P3.2-067), ocrelizumab (P3.2-054), IFNb-1b (P3.2-080), PEG-IFN-1a (P3.2-082) Sequencing studies (P3.2-050, P3.2-056, P3.2-070, P3.2-075, P3.2-103) Brain atrophy: DMF (P3.2-064) Real-world studies: DMF (P3.2-081) Clinical tips: Steroid…

AAN Poster Picks – Monday, May 6, 2019

May 6, 2019

…phine (P2.8-053) Suicidal behaviour (P2.8-025) Multiple sclerosis – Basic science Bruton’s tyrosine kinase inhibition (P2.2-063, P2.2-077) Myelin-reactive CD8+ T cells (P2.2-065) DMF and IgG (P2.2-069), and GM-CSF-producing Th1 cells (P2.2-071) PPMS: and antibodies (P2.2-073); and NfL (P2.2-082); and CSF (P2.2-092) Traumatic brain injury Brain volume loss (P2.9-045) Fluid/MRI biomarkers (P2.9-057)…

Europe restricts alemtuzumab use for MS

May 1, 2019

…ists one case of ischemic stroke with hemiplegia and facial paresis in a 50-year-old woman treated with alemtuzumab; the case was reported in 2015 (https://cvp-pcv.hc-sc.gc.ca/arq-rei/report-rapport.do?lang=en&id=000655958). In published reports, there were two deaths in the phase II CAMMS223 trial that were possibly related to alemtuzumab: a 45-year-old female who died of an unspecified cardiovascular disorder two months after receiving the third…